Retinal Vasculitis Treatment Market Size, Share, and Trends 2024 to 2034

The global retinal vasculitis treatment market size accounted for USD 544.26 million in 2024, grew to USD 575.76 million in 2025 and is predicted to be worth around USD 949.09 million by 2034, registering a CAGR of 5.71% between 2024 and 2034. The North America retinal vasculitis treatment market size is evaluated at USD 250.54 million in 2024 and is estimated to grow at CAGR of 5.81% during the forecast period.

  • Last Updated : October 2024
  • Report Code : 5143
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID-19 Impact on Retinal Vasculitis Treatment Market 

5.1. COVID-19 Landscape: Retinal Vasculitis Treatment Industry Impact

5.2. COVID-19  Impact Assessment for the Industry

5.3. COVID-19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Retinal Vasculitis Treatment Market, By Infection Type

8.1. Retinal Vasculitis Treatment Market, by Infection Type, 2024-2034

8.1.1. Bacterial

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Viral

8.1.2.1. Market Revenue and Forecast (2021-2034)

8.1.3. Fungal

8.1.3.1. Market Revenue and Forecast (2021-2034)

8.1.4. Parasitic

8.1.4.1. Market Revenue and Forecast (2021-2034)

8.1.5. Rickettsia

8.1.5.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global Retinal Vasculitis Treatment Market, By Drug Type

9.1. Retinal Vasculitis Treatment Market, by Drug Type, 2024-2034

9.1.1. Oral Corticosteroid Drug

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. Hydrocortisone

9.1.2.1. Market Revenue and Forecast (2021-2034)

9.1.3. Prednisolone

9.1.3.1. Market Revenue and Forecast (2021-2034)

9.1.4. Prednisone

9.1.4.1. Market Revenue and Forecast (2021-2034)

 

9.1.5. Immunosuppressive Agent

9.1.5.1. Market Revenue and Forecast (2021-2034)

9.1.6. Azathioprine

9.1.6.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global Retinal Vasculitis Treatment Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.1.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.1.3.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.1.4.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.2.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.2.3.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.2.4.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.2.5.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.2.6.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.3.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.3.3.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.3.4.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.3.5.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.3.6.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.4.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.4.3.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.4.4.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.4.5.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.4.6.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.5.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.5.3.2. Market Revenue and Forecast, by Drug Type (2021-2034)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Infection Type (2021-2034)

10.5.4.2. Market Revenue and Forecast, by Drug Type (2021-2034)

Chapter 11. Company Profiles

11.1. Celgene Corporation

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Novartis AG

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. F. Hoffmann-La Roche

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. GlaxoSmithKline plc

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Bristol-Myers Squibb Company

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Human Genome Sciences, Inc.

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Novartis AG

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Bristol-Myers Squibb Company

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Novo Nordisk A/S

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. RNL BIO Co., Ltd.

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client